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changed therapy. In the oral treatment group 32% of patients are adherent to
their first-line treatment and 54% have changed treatment. Probabilistic-sensi-
tivity-analyses demonstrated the robustness of the model regarding assump-
tions and input-parameters. CONCLUSIONS: A treatment switch to Paliperidone
palmitate is a cost-effective alternative, improves treatment adherence and
reduces health-care costs in the future and leads to higher quality-of-life.
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OBJECTIVES: Despite of the controversy of antidepressant use during the gesta-
tional period, the reported antidepressant use at any time during pregnancy has
increased. This study aimed to explore antidepressant use behavior (persis-
tence) in low income, insured pregnant women in U.S. METHODS: This retro-
spective study using South Carolina Medicaid claims data (2004-2009) identified
eligible pregnant women (18 years) who were diagnosed with depression and
filled at least two antidepressant prescriptions during pregnancy. Type of anti-
depressant prescribed for pregnant women, length of therapy, antidepressant
use history before pregnancy, and trimester of antidepressant initiation were
measured to describe antidepressant use patterns. Our main outcome measure
was persistence with antidepressant therapy during pregnancy. Failure to per-
sist was defined as having a gap between two consecutive prescriptions of at
least 15 days. A Cox regression model was applied to identify predictors asso-
ciated with the risk for non-persistence with antidepressants in pregnant
women. RESULTS: Of 804 pregnant women meeting the study criteria, 78% took
selective serotonin reuptake inhibitors (SSRIs) during pregnancy, 39% had his-
tory of antidepressant use during 1 year before pregnancy, and less than 40%
initiated therapy during the first trimester. The average length of antidepres-
sant therapy during pregnancy was 114 days. Nearly 55% of women were per-
sistent without a gap ( 15 days) after initiation of antidepressant therapy.
Black women were 33% more likely to be non-persistent with antidepressants
during pregnancy than white women. Women with history of antidepressant
use during 1 year before pregnancy were 44% more likely to be non-persistent
with the therapy. CONCLUSIONS: Persistence with antidepressants was poor
during pregnancy in low income, insured pregnant women. Further studies are
needed to examine associations between persistence with antidepressants dur-
ing pregnancy and maternal and newborn outcomes.
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OBJECTIVES: To give a literature review and assess the health status utility and
productivity of adult patients with attention-deficit/hyperactivity disorder
(ADHD) focusing on measures with outstanding importance for health eco-
nomic analysis. METHODS: PubMed was systematically reviewed for adult
ADHD studies involving the EQ-5D and/or Work Productivity and Activity Im-
pairment (WPAI) questionnaires. A cross sectional survey in an outpatient psy-
chiatry centre was performed and the Clinical Global Impression scale (CGI-S)
was used to categorize patients by severity. RESULTS: While several studies
assessed the impact of ADHD in childhood only one (Patient 2011;4(4):247-57)
dealt with EQ-5D in adult patients and none applied WPAI. In our survey, forty-
four patients (males 79.5%) were involved with mean (SD) age of 30.0 (9.9) years
and disease duration of 7.6 (6.6) years. Thirty-three (75%) were singles, 9 (20.5%)
married (20.5%), 2 (4.5%) divorced and 9 (20.5%) had children. Highest educa-
tional level was primary, secondary school and university at 5 (11.4%), 22 (50.0%)
and 17 (38.7%) cases, respectively. Twenty-nine (65.9%) were taking medication
for ADHD, seven (15.9%) needed accompanying person when travelling for
health care. Injury requiring medical care occurred at 6 (13.6%) patients, 4 re-
lated to ADHD by self-report. Usual activities, pain/discomfort and anxiety/
depression were the most affected EQ-5D dimensions (moderate problem:
52.3%, 47.7%, 54.5%) and the EQ-5D score (mean 0.747, SD 0.280) was signifi-
cantly lower than the age-matched population norm (p0.05). Utility in mild
(CGI-S3) and moderate (CGI-S4) health state was 0.799 and 0.706, respec-
tively. Twenty-three (52.3%) patients were working, 17 (38.6%) were students
and 4 (9.1%) unemployed. WPAI results were as follows, mean (SD): absenteeism
0.1 (0.3)%, presenteeism 33.0 (26.2)%, overall work impairment 16.9 (22.8)%, ac-
tivity impairment 39.5 (28.7)%. CONCLUSIONS: Health status utility and produc-
tivity in adult ADHD is underexplored. Our study suggests that impaired every-
day activities and preseenteism are considerable and deserve further research.
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OBJECTIVES: To assess preferences, using the time trade-off (TTO), regarding fre-
quencies of having to go for a doctor’s visit to receive pharmacological injections
for the treatment of schizophrenia.METHODS:A survey was conducted in Sweden;
respondents including 259 patients with a serious mental disorder, 263 relatives of
individuals suffering from a serious mental disorder, and 528 people sampled from
the general population were recruited for the purpose of this study. A time trade-
off (TTO) study design was used to elicit the utility of decreasing the frequency of
necessary doctor visits. Average utilities were calculated for each health state for
each respondent group. The marginal disutility of an additional yearly visit to the
doctor was estimated using a standard OLS regression with an intercept. Bootstrap-
ping was utilized to compute 95% confidence intervals around utilities and mar-
ginal disutilities. RESULTS: The marginal disutility of an additional doctor visit was
found to be 0.0041 for patients, 0.0022 for relatives, 0.0017 for the general popula-
tion and 0.0022 for an average respondent. For an average respondent across all
groups, this corresponded to an additional utility of 0.031 between having to visit
the doctor for an injection once a month versus every other week and 0.048 be-
tween having to visit the doctor for an injection once every 3 months versus every
other week. CONCLUSIONS: The results are suggestive of a general trend of in-
creased reported disutility for a higher number of doctor visits for an injection per
year across all respondent groups.
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OBJECTIVES: To systematically identify and review published evidence on health-
state utility weights in paediatric and adolescent ADHD.METHODS:Utility weights
were identified as part of a wider systematic review, which was performed to
identify input parameter values for an economic model in ADHD. PubMed, EM-
BASE, Cochrane National Health Service’s Economic Evaluation Database, EconLit,
and Health Economic Evaluations Database were searched from 1960 to May 2011.
The review focused on articles reporting utility weights in ADHD by level of treat-
ment response. RESULTS: A total of 1,648 unique titles and abstracts were re-
trieved; 1,630 records were excluded upon title (or abstract) review and 12 upon
full-text review. The review included 6 studies reporting utilities by level of re-
sponse, 2 of which further stratified utilities by treatment type. One study reported
utilities for 4 health states (‘normal’, ‘borderline to mildly ill’, ‘moderately to mark-
edly ill’, and ‘severely ill’). One study used the EQ-5D instrument completed by
parents; 2 assessed parents’ preferences using standard gamble; 1 used statistical
mapping (for responder and nonresponder states) and time trade-off (TTO) inter-
views and visual analogue scales (for 4 disease-severity health states); 1 calculated
scores from other utility studies; and 1 did not report methods explicitly. Utilities
for responders ranged between 0.98 and 0.80; utilities for non-responders ranged
between 0.93 and 0.70. TTO-derived utilities for the 4 health states were rated by
members of the general public and ranged from 0.839 (’normal’) to 0.444 (’severely
ill’). The review assessed the methodological compliance of each included study
with NICE Reference Case. CONCLUSIONS: Our review identified utility estimates
potentially suitable for use in ADHD economic evaluations. Appropriateness of
these for inclusion in a particular analysis needs to be assessed in terms of the
modelled heath states and the clinical outcomes used to define these.
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OBJECTIVES: To validate the clinically useful depression outcome scale (CUDOS)
for evaluating the severity of depressive symptoms in patients with major depres-
sive disorder (MDD) attending a Primary Care Service. METHODS: An epidemiolog-
ical, cross-sectional, multicentre study was conducted including adult patients
diagnosed as MDD according to the DSM-IV TR during the last 3 months. The
following instruments were applied: Primary Care Evaluation of Mental Disorders
(PRIME-MD), Hamilton Rating Scale for Depression (HAMD-17), CUDOS, Social and
Occupational Functioning Assessment Scale (SOFAS), SF-36 (Physical –PCS- and
Mental –MCS- Component Summaries) and the Clinical global Impression for Se-
verity of Illness (CGI-SI). CUDOS feasibility, internal consistency (Cronbach=s ),
convergent validity (Spearman correlation with SOFAS, HAMD-17 and SF-36) and
discriminant validity (differences in CUDOS values according to HAMD-17 classifi-
cation of severity and the CGI-SI: Kruskal-Wallis and Mann-Whitney U –Bonferroni
correction-) were evaluated. Finally, a cut-off score (Receiver Operation Curve-
ROC- analysis) was calculated using the HAMD-17 as criterion (0-7 remission).
RESULTS: In total, 305 MDD patients with a mean age (SD) of 51.75 (15.53) years
(30.5% males) were interviewed. According to the HAMD-17, 7.9% of patients were
in remission, 29.8% suffered from mild depression, 22.0% moderate depression,
21.0% severe and 19.3% very severe. Mean(SD) time for completion was 4.47(2.4)
minutes and floor or ceiling effects were found in less than 1% of patients. Cron-
bach=s  was high (0.877). Correlations with CUDOS were: -0.402(SOFAS),
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0.431(HAMD-17), -0.224(PCS), -0.650(MCS) -all p0.001-. Differences in CUDOS
scores between severity levels were found (p0.03-Bonferroni correction-). The
ability of CUDOS for predicting remission was adequate (AUC 0.837; CI 0.740-
0.934; p0.001. A cut-off point (CUDOS 24) was estimated (sensitivity0.81, spec-
ificity 0.77). CONCLUSIONS: The Spanish version of the CUDOS is a reliable and
valid measure of depression which can detect MDD patients with a suboptimal
response and be easily used during clinical practice in Primary Care.
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OBJECTIVES: To identify symptoms and functional impacts associated with major
depressive disorder (MDD) using concept elicitation interviews with patients to
determine relevant concepts for assessment in patient-reported outcome (PRO)
measures.METHODS:Qualitative interviews were conducted at 6 U.S. clinical sites
for cross-sectional assessment in a sample of adults (18-65 years) meeting DSM-
IV-TR criteria for MDD with a depressive episode within the last 6 months and
HAM-D score 18 at screening. Semi-structured individual interviews conducted
by trained research staff used open-ended questions and day-reconstruction exer-
cises to elicit spontaneous reports of symptom/impact concepts. Subsequent prob-
ing was used to assess concepts not spontaneously reported by subjects. Inter-
views were audio-recorded and transcribed. Transcripts were coded and analyzed
using Atlas.ti and summarized by like-content. Interview guide notations were
used to tag concepts offered by either spontaneous or probed report. RESULTS: A
total of 40 interviews were conducted with subjects (mean age: 46.211.8; 67.5%
female) representing a broad range of demographic characteristics. Saturation of
concepts was achieved within the first 32 interviews. Symptoms identified by the
majority of subjects included: Sadness (80.0% of subjects overall [and 52.5% spon-
taneously]), Tiredness (75.0[65.0]), Anger (72.5[57.5]), Loneliness (70.0[45.0]), Diffi-
culty Falling Asleep (67.5[55.0]), Low Self-Esteem (65.0[32.5]), Anxiety (62.5[55.0]),
Guilt (62.5[42.5]), Trouble Focusing (60.0[42.5]), Difficulty Waking (60.0[35.0]), Fa-
tigue (57.5[50.0]) and Irritability (57.5[42.5]). The most frequently reported impacts
were: Having Fewer Friends (92.5[65.0]), Feeling Isolated (82.5[57.5]), Dropping Daily
Activities (82.5[55.0]), Difficulty with Chores (77.5[30.0]), Interpersonal Difficulties
(72.5[37.5]), Workplace Difficulties (65.0[52.5]) and Neglecting Self-Hygiene
(65.0[17.5]). CONCLUSIONS: Symptoms and functional impacts associated with
MDD were identified through qualitative interviews. Relevant patient-identified
concepts should be considered in the development of patient-reported outcomes.
Concepts reported spontaneously provide good support for relevance, whereas
other concepts identified primarily through probing may not offer the best candi-
dates for assessment. Strength of these findings is suggested by achievement of
concept saturation.
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OBJECTIVES: To identify ways patients describe Major Depressive Disorder (MDD)
symptoms and impacts so new patient-reported outcome (PRO) measures can ef-
fectively incorporate the patient’s voice and perspective. METHODS: Qualitative
interviews were conducted with adult MDD patients (18-65 years) recruited from 6
US clinical sites. Patients were required at screening to have a Hamilton Depression
Rating Scale (HAM-D) score of18 and suffer depression within the past 6 months.
Individual interviews conducted by trained researchers used a semi-structured
interview guide designed to elicit responses about MDD symptoms and related
impacts. Interviews were audio-recorded, transcribed, cataloged and organized
into a coding framework using Atlas.ti software for content analysis. RESULTS:
Forty interviews were conducted. Mean age of participants was 46.2 (SD11.8);
67.5% were female, and 45.0% described their race as white. Saturation of concepts
was achieved within the first 32 interviews. A total of 3022 symptom and 830
impact code stems were derived from the transcripts. Eleven different domains
were developed in the coding framework for symptoms. Domains with the greatest
number of symptom expressions included Emotions/Mood (624/3022 [20.6%] of
expressions), Anxiety (398/3022 [13.2%]), and Cognition (358/3022 [11.8%]). Four dif-
ferent impact domains were identified, with Difficulty with Daily Activities (340/
830 [41.0%]) and Social/Relationship Changes (319/830 [38.4%]) receiving the great-
est number of expressions. A variety of different descriptions were used to
communicate these domains and sub-domains; representative quotations will be
presented. CONCLUSIONS: A broad range of concepts and terminology is used by
patients to describe the symptoms and impacts associated with their depression.
Participants identified symptoms that included both expected (based on diagnostic
criteria) and those not commonly described as core symptoms of MDD. Organiza-
tion of quotations into a coding framework and dictionary allows for the selection
of concepts and incorporation of the most meaningful patient language into early
stages of PRO instrument development.
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OBJECTIVES: Dysuria, xerostomia, anxiety and depression after initiation of treat-
ment with inhaled medicine have not been fully evaluated. The aim of this study
was to investigate the impact of treatment with inhaled drugs on these symptoms.
METHODS: This was a multicenter, prospective study conducted in 3 respiratory
clinics in Korea. The symptoms of dysuria, xerostomia, anxiety and depression
were observed via the International Prostate Symptoms Score (IPSS), Xerostomia
questionnaire (XQ), Hospital Anxiety & Depression Scale (HADS) at the baseline, 4
weeks, 12 weeks after initiation of inhalation therapy. The patients were divided
into two subgroups according to inhaler medication (: combination of inhaled
corticosteroids (ICS) and Long-acting 2-agonist (LABA) II: Long-acting muscarinic
antagonist (LAMA)). RESULTS: Among 90 patients enrolled, 84 patients were ana-
lyzed. After initiation of treatment with inhaled drugs, IPSS and XQ were not
changed significantly (IPSS, 11.969.85, 12.98 9.88, 13.85 0.08; XQ, 8.92 10.96,
10.31  11.33, 11.42  12.82 in the baseline, 4 weeks, 12 weeks respectively). HADS
at 12 weeks were significantly higher than that in the baseline. (p0.037) (9.61 
5.18, 10.36 6.07, 10.85  6.27 in the baseline, 4 weeks, 12 weeks respectively).
CONCLUSIONS: This study results indicate that Inhaler adversely affected dysuria,
xerostomia, anxiety and depression in new inhaler uses. But those differences
were not statistically significant except HADS. And further large sample size study
is needed.
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OBJECTIVES: 1) to identify concepts relevant to patients when measuring cognitive
symptoms of depression and their impacts, and 2) to adapt an existing patient-
reported measure of cognitive function for MDD. METHODS: Four age-stratified
focus groups (total N  33) were conducted with adults under treatment for MDD.
Following open concept elicitation, participants provided feedback on two self-
report measures of cognitive symptoms: the Applied Cognition General Concerns
Scale (Gerson et al., 2006) and the Perceived Deficits Questionnaire (PDQ) (Sullivan
et al., 1990). Focus group results led to a modified PDQ for MDD. Two sets of cogni-
tive interviews with additional MDD patients (N  17) refined the instrument,
resulting in the PDQ for Depression (PDQ-D). RESULTS: Focus group participants
reported seven different categories of cognitive symptoms. Across the age strata,
the most bothersome were difficulties with concentration, attention and memory.
Patients described many ways their cognitive symptoms affected them; productiv-
ity limitations were among the most salient. While most focus group participants
deemed the PDQ content appropriate, a shorter reference period and more explicit
response options were suggested. Cognitive interview results suggested that the
initial version of the 20-item PDQ-D was an appropriate and comprehensive as-
sessment of cognitive symptoms of MDD. Interview participants found the items
easy to understand and answer. Minor modifications made in early interviews
facilitated completion of the measure in later interviews. CONCLUSIONS: The
PDQ-D is a patient-reported assessment of cognitive function with potential to
provide unique information important for comprehensive evaluation of individual
patients with MDD and new treatments for this disorder.
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OBJECTIVES: To model the longitudinal latent effect on self-reported changes in
sleep disturbances and disability of adding pregabalin (PGB) to the usual care (UC)
therapy of outpatients with GAD treated in routine (Real World) clinical practice.
METHODS: A post-hoc analysis was performed using refractory outpatients with
GAD enrolled in a 6-month, prospective study carried-out in psychiatric clinics.
Anxiety symptoms, self-reported sleep disturbances and disability changes at end-
of-trial visit were assessed with the Hamilton-Anxiety (HAM-A), MOS-sleep and
WHO-DAS-II scales, respectively. Adding PGB to the UC was compared to UC alone
and its direct and indirect effects (expressed in percentages as the total effect
explained by the model) were estimated by means of a conditional latent curve
model applying structural equation modeling, with treatment as exogenous vari-
able, and anxiety as covariates. RESULTS: A total of 1546 (68% women, mean age;
45.5 years) PGB naïve patients were included in the analysis. Either symptoms of
anxiety, sleep disturbances or disability scores were significantly improved at end-
of-trial, with higher scores reduction in the cohort adding PGB: -15.92 vs. -14.48 in
HAM-A (F4.9, p0.027), -29.67 vs. -23.98 in MOS-sleep (F16.3, p0.001), and
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